Dublin, Feb. 18, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/kr..._market_by ) has announced the addition of the "Vaccine Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019 " report to their offering.
The vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%
The global vaccine technology market involves different human vaccines that help in the prevention and treatment of diseases such as cholera, typhoid, and influenza. Vaccine technology market is driven by several factors which include high prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. The emerging market and increasing vaccine research have opened an array of opportunities for growth of the market. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of market.
The vaccine technology market by type is divided into preventive and therapeutic vaccines. Preventive vaccines accounted for the largest share of the market primarily due to the increasing prevalence of infectious diseases. In addition, increasing investments by government and non-government organizations to enhance vaccine research and supply doses worldwide will further enhance the growth of market.
On the basis of technologies, the vaccines market is classified into live attenuated, toxoid, conjugate, subunit, recombinant vector, inactivated, synthetic, and dendritic cell vaccines. The subunit vaccines segment accounted for the largest share of the market. Increasing research activities for development of more effective and safe vaccines will drive the growth of market.
The disease indication vaccine technology market is segmented into infectious diseases, cancer, and allergy. The infectious diseases segment accounted for a major share of market. Growth in this segment can be attributed to the high prevalence of infectious diseases and increasing government initiatives to improve immunization programs across the globe. The infectious diseases segment is further categorized into pneumococcal, influenza, DTP, hepatitis, rotavirus, varicella, meningococcal, polio, MMR and others. The cancer segment is classified as cervical cancer and others.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Industry Insights
7 Vaccines Market, By Technology
8 Vaccines Market, By Type
9 Vaccines Market, By Disease Indication
10 Vaccines Market, By End User
11 Global Vaccine Technology Market, By Region
12 Competitive Landscape
13 Company Profiles
- Bavarian Nordic
- CSL Limited
- Emergent Biosolutions, Inc.
- Glaxosmithkline, PLC.
- Johnson & Johnson
- Medimmune, LLC. (A Subsidiary of Astrazeneca)
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- SANOFI
For more information visit http://www.researchandmarkets.com/research/kr..._market_by
CONTACT: CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals
